Alopecia in patients treated with molecularly targeted anticancer therapies.

about

Alopecia in patients treated with molecularly targeted anticancer therapies.

Item

http://www.wikidata.org/entity/Q36316632

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Alopecia in patients treated with molecularly targeted anticancer therapies.

@ast

Alopecia in patients treated with molecularly targeted anticancer therapies.

@en

type

Item

label

Alopecia in patients treated with molecularly targeted anticancer therapies.

@ast

Alopecia in patients treated with molecularly targeted anticancer therapies.

@en

prefLabel

Alopecia in patients treated with molecularly targeted anticancer therapies.

@ast

Alopecia in patients treated with molecularly targeted anticancer therapies.

@en

P1476

Alopecia in patients treated with molecularly targeted anticancer therapies

@en

P2093

C Ensslin

http://www.w3.org/2001/XMLSchema#string

K J Busam

http://www.w3.org/2001/XMLSchema#string

K Marulanda

http://www.w3.org/2001/XMLSchema#string

L Gorcey

http://www.w3.org/2001/XMLSchema#string

P A Gerber

http://www.w3.org/2001/XMLSchema#string

S Wu

http://www.w3.org/2001/XMLSchema#string

T Parikh

http://www.w3.org/2001/XMLSchema#string

P2860

Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Meta-analysis in clinical trials

Sorafenib in advanced hepatocellular carcinoma

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

Sorafenib in advanced clear-cell renal-cell carcinoma

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

P304

2496-2502

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

meta-analysis

P356

10.1093/ANNONC/MDV390

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Mario E Lacouture

V R Belum

P577

2015-09-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26387145

http://www.w3.org/2001/XMLSchema#string

P932

4658542

http://www.w3.org/2001/XMLSchema#string